KR850008154A - N, 3-disubstituted 2-oxyindole-1-carboxamide - Google Patents

N, 3-disubstituted 2-oxyindole-1-carboxamide Download PDF

Info

Publication number
KR850008154A
KR850008154A KR1019850003013A KR850003013A KR850008154A KR 850008154 A KR850008154 A KR 850008154A KR 1019850003013 A KR1019850003013 A KR 1019850003013A KR 850003013 A KR850003013 A KR 850003013A KR 850008154 A KR850008154 A KR 850008154A
Authority
KR
South Korea
Prior art keywords
carbon atoms
alkyl
formula
hydrogen
chloro
Prior art date
Application number
KR1019850003013A
Other languages
Korean (ko)
Other versions
KR870000497B1 (en
Inventor
베르나르드 카딘 사울
Original Assignee
윌리암 데이비스 휸
화이자 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리암 데이비스 휸, 화이자 인코퍼레이티드 filed Critical 윌리암 데이비스 휸
Publication of KR850008154A publication Critical patent/KR850008154A/en
Application granted granted Critical
Publication of KR870000497B1 publication Critical patent/KR870000497B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/60Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음No content

Description

N, 3-이치환된 2-옥시인돌-1-카복사마이드의 제조방법N, 3-disubstituted 2-oxyindole-1-carboxamide

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (9)

일반식(Ⅳ)의 화합물을 불활성 용매중에서 일반식 R2-H=C=O의 이소시아네이트와 반응시키거나, 일반식(Ⅴ)의 화합물을 불활성 용매중에서 일반식 R1-C(=O)-OH의 카복실산의 활성 유도체와 반응시킴을 특징으로하여, 일반식(Ⅰ)의 2-옥시인돌-1-카복사마이드 화합물 또는 약제학적으로 허용되는 그의 염을 제조하는 방법.The compound of formula (IV) is reacted with an isocyanate of the formula R 2 -H = C = O in an inert solvent, or the compound of formula (V) is formula R 1 -C (= O)-in an inert solvent. A process for preparing a 2-oxyindole-1-carboxamide compound of formula (I) or a pharmaceutically acceptable salt thereof, characterized by reacting with an active derivative of a carboxylic acid of OH. 상기 식에서, X는 수소, 폴루오로, 브로모, 탄소수, 1 내지 4의 알킬, 탄소수 3 내지 7의 사이 클로알킬 탄소수 1 내지 4의 알콕시, 탄소수 1 내지 4의 알킬티오, 트리폴루오로메틸, 탄소수 1 내지 4의 알킬설피닐, 탄소수 1 내지 4의 알킬설포닐, 니트로, 페닐, 탄소수 2 내지 4의 알카노일, 벤조일, 테노일, 탄소수 2 내지 4의 알칸아미도, 벤즈아미도 또는 각 알킬부위의 탄소수가 1 내지 3인,-디알킬설파모일이고 : Y는 수소, 폴루오로, 클로로, 브로모, 탄소수 1 내지 4의 알킬, 탄소수 3 내지 7의 사이클로 알킬, 탄소수 1 내지 4의 알콕시, 탄소수 1 내지 4의 알킬티오, 또는 트리폴루오로메틸이거나 : 또는 X및 Y가 함께 4,5-, 5,6-또는 6,7-메틸렌디옥시 그룹 또는 4,5-, 5,6-또는 6,7-에틸렌디옥시 그룹이거나 : 또는 X 및 Y가 함께, 인접한 탄소원자에 결합되어 있는 경우에는, 이가 라디칼 Z를 형성하며(이때, Z는,Wherein X is hydrogen, polouro, bromo, C1-C4 alkyl, C3-C7 cycloalkyl C1-C4 alkoxy, C1-C4 alkylthio, tripololomethyl , Alkylsulfinyl having 1 to 4 carbon atoms, alkylsulfonyl having 1 to 4 carbon atoms, nitro, phenyl, alkanoyl having 2 to 4 carbon atoms, benzoyl, tennoyl, alkanamido having 2 to 4 carbon atoms, benzamido or each C1-C3 alkyl group , -Dialkylsulfamoyl: Y is hydrogen, polouro, chloro, bromo, alkyl of 1 to 4 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkylthio of 1 to 4 carbon atoms, Or tripololomethyl: or X and Y together are 4,5-, 5,6- or 6,7-methylenedioxy groups or 4,5-, 5,6- or 6,7-ethylenedioxy Or when X and Y are bonded to adjacent carbon atoms together, they form a radical Z (wherein Z is 로 이루어진 그룹중에서 선택되며, 이때 W는 산소 또는 황이다) : R1은 탄소수 1 내지 6의 알킬, 탄소수 3 내지 7의 사이클로알킬, 탄소수 4 내지 7의 사이클로알케닐, 페닐 치환된 페닐, 알킬 부위가 탄소수 1 내지 3인 페닐알킬, 알킬 부위가 탄소수 1 내지 3인(치환된 페닐) 알킬, 알킬 부위가 탄소수 1 내지 3인 펜옥시알킬, 알킬 부위가 탄소수 1 내지 3인 (치환된 펜옥시)알킬, 알킬부위가 탄소수 1 내지 3인 (티오펜옥시)알킬, 나프틸 비사이클로[2.2.1] 헵탄-2-일, 비사이클로[2.2.1] 헵트-5-엔-2-일 또는 -(CH2)n-Q-R0이고 : 이때, 치환된 페닐, (치환된페닐)알킬 및 (치환된 펜옥시)알킬상의 치환체는 폴루오로, 클로로, 브로모, 탄소수 1 내지 4의 알킬, 탄소수 1 내지 4의 알콕시 또는 트리폴루오로메틸이며 : n은 0,1 또는 2이고 : Q는 푸란, 티오펜, 피롤, 피라졸, 이미다졸, 티아졸, 이소티아졸, 옥사졸, 이속사졸, 1,2,3-티아디아졸, 1,3,4-티아디아졸, 1,2,5티아디아졸, 테트라하이드드로푸란, 테트라하이드로티오펜, 테트라하이드로피란, 테트라하이드로피란, 피리딘, 피리미딘, 피라진, 벤조[b] 푸란 및 벤조[b]티오펜으로 이루어진 그룹중에서 선택된 화합물로부터 유도된 이가의 라디칼이고 : R0는 수소 또는 탄소수 1 내지 3의 알킬이며 : R2는 탄소수 1 내지 6의 알킬, 탄소수 3 내지 7의 사이클로알킬, 벤질, 푸릴, 티에닐, 피리딜 또는 식의 그룹이다(이때 R3및 R4는 각각 수소, 폴루오로, 클로로, 탄소수 1 내지 4의 알킬, 탄소수 1 내지 4의 알콕시 또는 트리폴루오로메틸이다.).And W is oxygen or sulfur): R 1 is alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkenyl having 4 to 7 carbon atoms, phenyl substituted phenyl, and alkyl moiety. A phenylalkyl having 1 to 3 carbon atoms, an alkyl moiety having 1 to 3 carbon atoms (substituted phenyl), a phenoxyalkyl having 1 to 3 carbon atoms, an alkyl moiety having 1 to 3 carbon atoms (substituted phenoxy) Alkyl, (thiophenoxy) alkyl having 1 to 3 carbon atoms, naphthyl bicyclo [2.2.1] heptan-2-yl, bicyclo [2.2.1] hept-5-en-2-yl, or- (CH 2 ) nQR 0 : wherein the substituents on substituted phenyl, (substituted phenyl) alkyl and (substituted phenoxy) alkyl are poloo, chloro, bromo, alkyl of 1 to 4 carbon atoms, 1 to 4 carbon atoms Alkoxy or tripololomethyl of 4: n is 0,1 or 2: Q is furan, thiophene, pyrrole, pyrazole, imidazole , Thiazole, isothiazole, oxazole, isoxazole, 1,2,3-thiadiazole, 1,3,4-thiadiazole, 1,2,5 thiadiazole, tetrahydrofuran, tetrahydro A divalent radical derived from a compound selected from the group consisting of thiophene, tetrahydropyran, tetrahydropyran, pyridine, pyrimidine, pyrazine, benzo [b] furan and benzo [b] thiophene: R 0 is hydrogen or carbon number Alkyl of 1 to 3: R 2 is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, benzyl, furyl, thienyl, pyridyl or formula (Wherein R 3 and R 4 are each hydrogen, polouro, chloro, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms or tripoloromethyl). 제1항에 있어서, X가 5-위치 또는 6-위치에 있고 수소, 폴루오로, 클로로, 브로모 또는 트리폴루 오로메틸이고 ; Y는 수소이며, R1은 탄소수 1 내지 6의 알킬, 탄소수 3 내지 7의 사이클로알킬, 푸릴, 티에닐, 알킬 부위의 탄소수가 1 내지 3인 페닐알킬, 푸릴메틸, 티에닐메틸 또는 트리폴루오로메틸이고 ; R2는 탄소수 1 내지 6의 알킬, 탄소수 3 내지 7의 사이클로알킬 또는 다음 일반식의 그룹인 일반식(Ⅰ)의 2-옥시인돌-1-카복사마이드 화합물 또는 약제학적으로 허용되는 그의 염을 제조하는 방법.2. A compound according to claim 1, wherein X is in the 5-position or 6-position and is hydrogen, polouro, chloro, bromo or tripoloromethyl; Y is hydrogen and R 1 is alkyl having 1 to 6 carbons, cycloalkyl having 3 to 7 carbons, furyl, thienyl, phenylalkyl having 1 to 3 carbon atoms in the alkyl moiety, furylmethyl, thienylmethyl or tripolo Romethyl; R 2 represents an alkyl having 1 to 6 carbon atoms, a cycloalkyl having 3 to 7 carbon atoms, or a 2-oxyindole-1-carboxamide compound of formula (I) which is a group of the following general formula: or a pharmaceutically acceptable salt thereof. How to manufacture. (이때 R3및 R4는 각각 수소, 폴루오로, 클로로, 탄소수 1 내지 4의 알킬, 탄소수 1 내지 4의 알콕시 또는 트리폴루오로메틸이다.)(Wherein R 3 and R 4 are hydrogen, polouro, chloro, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms or tripoloromethyl, respectively.) 제1항 또는 2항에 있어서, 일반식(Ⅳ)의 화합물을 불활성 용매중, 50 내지 150℃ 범위의 온도에서, 거의 1몰 당량의 일반식 R3-N=C=O의 이소시아네이트와 반응시킴을 특징으로하는 방법.The compound of formula (IV) is reacted with an isocyanate of general formula R 3 -N = C═O in an inert solvent at a temperature in the range of 50 to 150 ° C. Characterized by. 상기 식에서, X, Y, R1및 R2는 제1항 또는 2항에서 정의된 바와 같다.Wherein X, Y, R 1 and R 2 are as defined in claim 1 or 2. 제3항에 있어서, 지방족 탄화수소, 방향족 탄화수소, 염소화 탄화수소, 에테르,,-디메틸포름아마이드,,-디메틸아세트아마이드, N-메틸피롤리돈 및 디메틸 설폭사이드로부터 선택되는 용매중에서 반응을 수행함을 특징으로하는 방법.The process according to claim 3, wherein the aliphatic hydrocarbons, aromatic hydrocarbons, chlorinated hydrocarbons, ethers, , Dimethylformamide, , The reaction is carried out in a solvent selected from dimethylacetamide, N-methylpyrrolidone and dimethyl sulfoxide. 제1항 또는 2항에 있어서, 일반식(Ⅴ)의 화합물을 -10 내지 25℃ 범위의 온도에서, 1 내지 4몰 당량의 염기성 제제의 존재하에서, 불활성 용매중에서, 1몰 당량또는 약간과량의 일반식 R1-C(=O)-OH의 카복실산의 활성유도체와 반응시킴을 특징으로하는 방법.The compound of formula (V) according to claim 1 or 2, wherein the compound of formula (V) is dissolved in an inert solvent in the presence of 1 to 4 molar equivalents of basic agent at a temperature in the range of -10 to 25 ° C. Reacting with an active derivative of a carboxylic acid of the general formula R 1 -C (═O) —OH. 상기 식에서, X, Y, R1및 R2는 제1항 또는 2항에서 정의된 바와 같다.Wherein X, Y, R 1 and R 2 are as defined in claim 1 or 2. 제5항에 있어서, 활성 유도체가 산 염화물이고 반응이 극성, 비양자성 용매중에서 이루어짐을 특징으로하는 방법.6. The process of claim 5 wherein the active derivative is an acid chloride and the reaction is in a polar, aprotic solvent. 제1항 또는 3 내지 6항중의 어느 하나에 있어서, Y가 수소이고 X가 수소, 5-클로로, 6-클로로, 5-플루오로 또는 6-플루오로임을 특징으로하는 방법.The method according to any one of claims 1 or 3 to 6, wherein Y is hydrogen and X is hydrogen, 5-chloro, 6-chloro, 5-fluoro or 6-fluoro. 제7항에 있어서, R1이 벤질, 2-푸릴, 2-티에닐, (2-푸릴)메틸 또는 (2-티에닐) 메틸임을 특징으로하는 방법.8. A process according to claim 7, wherein R 1 is benzyl, 2-furyl, 2-thienyl, (2-furyl) methyl or (2-thienyl) methyl. 제8항에 있어서, X가 5-클로로이고, R1이 2-푸릴이며 R2가 t-부틸임을 특징으로하는 방법.The method of claim 8, wherein X is 5-chloro, R 1 is 2-furyl and R 2 is t-butyl. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019850003013A 1984-05-04 1985-05-03 Process for the preparation of n,3-substituted 2-oxyindole-1-carboxamide KR870000497B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60735684A 1984-05-04 1984-05-04
US607,356 1984-05-04

Publications (2)

Publication Number Publication Date
KR850008154A true KR850008154A (en) 1985-12-13
KR870000497B1 KR870000497B1 (en) 1987-03-12

Family

ID=24431933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850003013A KR870000497B1 (en) 1984-05-04 1985-05-03 Process for the preparation of n,3-substituted 2-oxyindole-1-carboxamide

Country Status (25)

Country Link
JP (1) JPS60243068A (en)
KR (1) KR870000497B1 (en)
AR (1) AR241159A1 (en)
BG (2) BG60208B2 (en)
CS (1) CS252828B2 (en)
DD (1) DD232916A5 (en)
EG (1) EG17193A (en)
ES (2) ES8609248A1 (en)
FI (1) FI80016C (en)
HU (1) HU196057B (en)
IE (1) IE851103L (en)
IN (1) IN161509B (en)
MA (1) MA20424A1 (en)
MW (1) MW1685A1 (en)
MX (1) MX5839A (en)
NO (1) NO163132C (en)
OA (1) OA08098A (en)
PL (2) PL147508B1 (en)
PT (1) PT80375B (en)
RO (2) RO94455B (en)
RU (1) RU2017729C1 (en)
SU (1) SU1468413A3 (en)
YU (1) YU44998B (en)
ZA (1) ZA853324B (en)
ZW (1) ZW7885A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
IL95880A (en) * 1989-10-13 1995-12-31 Pfizer Use of 3-substituted-2-oxindole derivatives for the preparation of a pharmaceutical preparation for inhibiting interleukin-1 biosynthesis

Also Published As

Publication number Publication date
BG60207B2 (en) 1993-12-30
SU1468413A3 (en) 1989-03-23
ZA853324B (en) 1986-12-30
CS252828B2 (en) 1987-10-15
RO91141B (en) 1987-07-03
DD232916A5 (en) 1986-02-12
PT80375B (en) 1987-09-30
CS320285A2 (en) 1987-03-12
PL145416B1 (en) 1988-09-30
ES542813A0 (en) 1986-07-16
RO94455A (en) 1988-06-30
FI80016C (en) 1990-04-10
HU196057B (en) 1988-09-28
PL257892A1 (en) 1986-10-07
NO163132B (en) 1990-01-02
AR241159A2 (en) 1991-12-30
FI851756L (en) 1985-11-05
EG17193A (en) 1990-08-30
ES8707182A1 (en) 1987-07-16
ES551275A0 (en) 1987-07-16
MW1685A1 (en) 1986-09-10
ES8609248A1 (en) 1986-07-16
NO163132C (en) 1990-04-11
PL147508B1 (en) 1989-06-30
PT80375A (en) 1985-05-01
PL253203A1 (en) 1986-06-17
OA08098A (en) 1987-03-31
IE851103L (en) 1985-11-04
BG60208B2 (en) 1993-12-30
NO851774L (en) 1985-11-05
KR870000497B1 (en) 1987-03-12
RO94455B (en) 1988-07-01
AR241159A1 (en) 1991-12-30
JPH0335315B2 (en) 1991-05-27
RO91141A (en) 1987-06-30
YU73085A (en) 1988-04-30
HUT37754A (en) 1986-02-28
YU44998B (en) 1991-06-30
MA20424A1 (en) 1985-12-31
RU2017729C1 (en) 1994-08-15
MX5839A (en) 1993-11-01
FI851756A0 (en) 1985-05-03
IN161509B (en) 1987-12-19
ZW7885A1 (en) 1985-07-24
JPS60243068A (en) 1985-12-03
FI80016B (en) 1989-12-29

Similar Documents

Publication Publication Date Title
KR850006173A (en) Method for preparing 3-substituted 2-oxindole-1-carboxamide
CA2146961C (en) Heterobicyclic sulfonamide and sulfonic ester derivatives
EP1406620B1 (en) Vinyl phenyl derivatives as glk activators
KR850005824A (en) Method for preparing 1,3-disubstituted oxyindole compound
AU4377585A (en) Benzofuran derivatives
KR870004981A (en) Process for the preparation of heterocyclic oxophthalazinyl acetic acid
CA2464333A1 (en) Heteroindanes: a new class of potent cannabimimetic ligands
EP0223937A1 (en) Indoles substituted with heterocycles, intermediates, process for their preparation and medicaments
RU2005105696A (en) SUBSTITUTED THIENYL HYDROXAMIC ACIDS AS HISTONDEACETHYLASE INHIBITORS
PL166512B1 (en) Method of obtaining novel derivatives of azoxyindole
US3551571A (en) Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones
El-Sharkawy et al. Synthesis of some novel pyrimidine, thiophene, coumarin, pyridine and pyrrole derivatives and their biological evaluation as analgesic, antipyretic and anti-inflammatory agents
KR850008154A (en) N, 3-disubstituted 2-oxyindole-1-carboxamide
US5116854A (en) Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
EP0305947A1 (en) Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use
CA1338866C (en) Hydantoin derivatives
Mannam et al. Synthesis of novel 1‐(5‐(Benzylsulfinyl)‐3‐methyl‐1, 3, 4‐thiadiazol‐2 (3 H)‐ylidene)‐thiourea/urea derivatives and evaluation of their antimicrobial activities
KR850006174A (en) Method for preparing 2-oxindole-1-carboxamide
US4665194A (en) Process for making 2-oxindole-1-carboxamides and intermediates therefor
US4831032A (en) Cardiotonic benzimidazoles
KR860002505A (en) Method for preparing 2-oxindole derivatives
KR850004487A (en) Method for preparing substituted spiro pyridine derivatives
AU616336B2 (en) Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
KR890005126A (en) Method for preparing haloalkyl thiazole and haloalkyl thiazole prepared by this method
Rubab et al. A, Siddiqui SZ, Akhtar MN. S-Alkylated/aralkylated 2-(1H-indol-3-yl-methyl)-1, 3, 4-oxadiazole-5-thiol derivatives. 1. Synthesis and characterization

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050203

Year of fee payment: 19

EXPY Expiration of term